Linked Life Data

12684670

Source:http://linkedlifedata.com/resource/pubmed/id/12684670

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12684670rdf:typepubmed:Citationlld:pubmed
pubmed-article:12684670lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:12684670lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:12684670lifeskim:mentionsumls-concept:C0004114lld:lifeskim
pubmed-article:12684670lifeskim:mentionsumls-concept:C0006118lld:lifeskim
pubmed-article:12684670lifeskim:mentionsumls-concept:C1513046lld:lifeskim
pubmed-article:12684670lifeskim:mentionsumls-concept:C0037028lld:lifeskim
pubmed-article:12684670lifeskim:mentionsumls-concept:C1415102lld:lifeskim
pubmed-article:12684670lifeskim:mentionsumls-concept:C1149300lld:lifeskim
pubmed-article:12684670lifeskim:mentionsumls-concept:C0918012lld:lifeskim
pubmed-article:12684670pubmed:issue5lld:pubmed
pubmed-article:12684670pubmed:dateCreated2003-4-9lld:pubmed
pubmed-article:12684670pubmed:abstractTextMalignant astrocytomas are highly invasive, vascular neoplasms that comprise the majority of nervous system tumors in humans. A strong association has previously been made between malignancy in human astrocytic tumors and increased expression of certain fibroblast growth factor (FGF) family members. MG-160 is an intrinsic type I cysteine-rich membrane sialoglycoprotein that resides in the medial cisternae of the Golgi apparatus, highly homologous to CFR, chicken fibroblast growth factor receptor, and ESL-1, E-selectin ligand. MG-160 binds fibroblast growth factors (FGFs) and may be involved in the intracellular trafficking of FGFs and the regulation of cellular response to FGFs. In the present study MG-160 expression was evaluated in human brain tumors exhibiting varying degrees of malignancy. At the mRNA level MG-160 expression was inversely correlated with the histological grade of astrocytomas such that high levels of MG-160 were observed in low-grade astrocytomas and low levels in malignant astrocytomas. This differential expression of MG-160 mRNA was verified at the protein level using immunohistochemistry. Grade II astrocytomas displayed consistent and intense staining for MG-160 as seen in normal brain. In contrast to the lower grade tumors, grade IV astrocytomas exhibited variable and weaker expression of MG-160. Our results suggest that, MG-160 may participate in malignant progression in astrocytomas. In addition, other brain tumors and human astrocytoma cell lines were characterized for MG-160 expression.lld:pubmed
pubmed-article:12684670pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12684670pubmed:languageenglld:pubmed
pubmed-article:12684670pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12684670pubmed:citationSubsetIMlld:pubmed
pubmed-article:12684670pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12684670pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12684670pubmed:statusMEDLINElld:pubmed
pubmed-article:12684670pubmed:monthMaylld:pubmed
pubmed-article:12684670pubmed:issn1019-6439lld:pubmed
pubmed-article:12684670pubmed:authorpubmed-author:TeramotoAkira...lld:pubmed
pubmed-article:12684670pubmed:authorpubmed-author:TakahashiHiro...lld:pubmed
pubmed-article:12684670pubmed:authorpubmed-author:SugisakiYuich...lld:pubmed
pubmed-article:12684670pubmed:authorpubmed-author:GonatasNichol...lld:pubmed
pubmed-article:12684670pubmed:authorpubmed-author:MorrisonRicha...lld:pubmed
pubmed-article:12684670pubmed:authorpubmed-author:YamaguchiFumi...lld:pubmed
pubmed-article:12684670pubmed:issnTypePrintlld:pubmed
pubmed-article:12684670pubmed:volume22lld:pubmed
pubmed-article:12684670pubmed:ownerNLMlld:pubmed
pubmed-article:12684670pubmed:authorsCompleteYlld:pubmed
pubmed-article:12684670pubmed:pagination1045-9lld:pubmed
pubmed-article:12684670pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:meshHeadingpubmed-meshheading:12684670...lld:pubmed
pubmed-article:12684670pubmed:year2003lld:pubmed
pubmed-article:12684670pubmed:articleTitleIdentification of MG-160, a FGF binding medial Golgi sialoglycoprotein, in brain tumors: an index of malignancy in astrocytomas.lld:pubmed
pubmed-article:12684670pubmed:affiliationDepartment of Neurosurgery, Nippon Medical School, Tokyo 113-8603, Japan. fyamaguc@nms.ac.jplld:pubmed
pubmed-article:12684670pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12684670pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
entrez-gene:2734entrezgene:pubmedpubmed-article:12684670lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12684670lld:entrezgene
lhgdn:association:9191lhgdn:found_inpubmed-article:12684670lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12684670lld:pubmed